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Enantioselective catalysis is one of the most efficient ways to synthesize high-added-value
enantiomerically pure organic compounds. As the subtle details which govern enantioselection
cannot be reliably predicted or computed, catalysis relies more and more on a combinatorial
approach. Biocatalysis offers an attractive, and often complementary, alternative for the synthesis
of enantiopure products. From a combinatorial perspective, the potential of directed evolution
techniques in optimizing an enzyme’s selectivity is unrivaled. In this review, attention is focused
on the construction of artificial metalloenzymes for enantioselective catalytic applications. Such
systems are shown to combine properties of both homogeneous and enzymatic kingdoms. This
review also includes our recent research results and implications in the development of new
semisynthetic metalloproteins for the enantioselective hydrogenation of N-protected dehydro-
amino acids.
1. Introduction
The preparation of enantiomerically pure compounds for the
production of pharmaceuticals, agrochemicals, flavors, and
functional materials is one of the most actively pursued fields
in synthetic chemistry.1,2 The possibility of extending the
patent-life of a racemic compound by protecting a single
enantiomer (the so-called ‘‘chiral switch’’) attracts much
interest from industry in this area. It is interesting to note
that, despite the Thalidomide tragedy, only 40% of all dosage-
form drug sales in 2000 were of single enantiomer. The
worldwide sales of chiral drugs in single enantiomer
dosage form have been growing at an annual rate greater
than 10% in the past years. It is estimated that the future
growth rate will yield worldwide sales greater than 200 billion
Euros by 2008.1
Three main routes exist for the preparation of enantiomeri-
cally pure compounds: (i) enantiomer separation; (ii) trans-
formation of a chiral precursor from the chiral pool and (iii)
enantioselective reactions, either stoichiometric or catalytic.
In terms of atom economy, the use of enantioselective
catalysts, either heterogeneous, homogeneous or enzymatic, is
the most efficient and attractive. Metal-catalyzed enantiose-
lective transformations have received much attention during
the past three decades and have played a crucial role in the
development of modern synthetic methodologies.3 This*thomas.ward@unine.ch
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endeavor was rewarded with the 2001 Nobel Prize in
Chemistry for achievements in this field.4–6
Despite these efforts, it remains very difficult to predict the
outcome of a metal-catalyzed enantioselective reaction.
Indeed, the differences in energy involved in the transition
states leading to both enantiomers of the desired product are
too small to be reliably predicted. As a consequence, the
number of efficient enantioselective metal catalysts and the
corresponding substrates remains modest.7
In parallel to these developments, enzymatic catalysis has
emerged as an alternative tool for the synthesis of enantiopure
compounds.8,9 Both the academic- and the industrial commu-
nity view biocatalysis as a highly promising area of research,
especially for the development of sustainable technologies for
the production of complex active ingredients in pharmaceu-
ticals and in agrochemicals. Table 1 outlines some of the most
noteworthy features of homogeneous- and of enzymatic
catalysis.
Enzymes exquisitely tailor both the first- and the second
coordination sphere of their active site to afford efficient
and selective catalytic systems. This characteristic is
particularly difficult to achieve for homogeneous catalysts.
Indeed, the steric- and the electronic control of a homogeneous
catalyst is mostly limited to the first coordination sphere of
the metal. However, the role of the solvent and of the
counterion (typical second coordination sphere interactions)
often plays a determinant role in the performance of a
catalyst.
Biocatalysts are attractive because of their remarkable
chemo-, regio-, and stereoselectivity, their impressive catalytic
efficiency, and their reactivity in aqueous media. Although
these characteristics can be useful, they can also limit the
exploitation of biocatalysts.10
Homogeneous catalysts are often more tolerant than
enzymes towards variation in size of a substrate because of
the inherent single-handed, lock-and-key specificity of bioca-
talysts. Despite their difference in size, acetamidoacrylic- and
acetamidocinnamic acid are often both good substrates for
homogeneous hydrogenation catalysts.
Organometallic- and enzymatic catalysts generally exhibit
their most characteristic activities on different classes of
reactants: organometallic catalysts are especially effective with
nonpolar substances (e.g., H2, CO, and olefins), while
enzymatic catalysts are often most useful with polar, poly-
functional materials (e.g., carbohydrates, acid derivatives, and
biopolymers).
Biocatalysts have evolved to target a single functionality
even in the presence of other, perhaps more reactive,
functionalities: enzymes do not require protective groups.
Despite the initial high promises, the implementation of
biocatalytic processes so far has only been realized for a few
large-scale operations.9,10 In many cases, the industrial
application of enzymes is hampered by the instability of the
biocatalyst under process conditions.
Some of the inherent limitations of biocatalysts—including
small substrate scope, operational stability, and availability of
only one enantiomer of the product—have been recently
overcome, thus significantly expanding the scope of applica-
tions of biocatalysis. This has been made possible by the
implementation of new methods for evolving proteins of
interest and essaying their activity. Approaches to the design
of catalytic proteins include automated sequence design, in
which a novel catalytic site is engineered into a natural protein
by mutating a subset of residues, and de novo protein design,
which requires the simultaneous design of the entire backbone
structure and sequence.11–15 Directed evolution (i.e. genetic
optimization) combined with high-throughput screening have
significantly facilitated the optimization of customized enan-
tioselective enzymes.16–20 Although genetic engineering tech-
niques can improve the overall stability, the activity and the
selectivity of a biocatalyst, the de novo design of enzymes
remains very challenging. Monoclonal catalytic antibodies
open interesting opportunities in this field however.21,22
From these considerations, it appears that homogeneous-
and enzymatic catalysis are, in many respects, complementary.
In a biomimetic spirit, efforts are currently underway in
different groups to design enantioselective artificial metalloen-
zymes.23 The introduction of an achiral catalytic moiety, which
ensures activity, in a chiral pocket provided by a host protein is
expected to produce active and (enantio)selective hybrid
catalysts with a well defined second coordination sphere
provided by the host protein. Such hybrid systems should
display properties reminiscent of both homogeneous- and
enzymatic kingdoms.
2. Preparation of artificial metalloenzymes
To ensure localization of the metal-containing moiety (the
coenzyme) within the host protein, two complementary
strategies are currently being pursued by various groups for
the generation of artificial metalloenzymes:
(i) Covalent incorporation of a metal-containing coenzyme
(Section 2.1)
Table 1 Typical features of homogeneous- and enzymatic catalysis
Homogeneous catalysis Enzymatic catalysis
Enantiomers Both enantiomers accessible Single enantiomer
Reaction repertoire Large Small
Turnover numbers Small Large
Solvent compatibility Organic . Aqueous Aqueous . Organic
Optimization Chemical Genetic
Second coordination sphere Ill-defined Well-defined
Functional group tolerance Small (protective groups) Large
Substrate scope Large Limited
Typical substrates Apolar Flexible
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(ii) Non-covalent (i.e. supramolecular) incorporation of a
metal-containing coenzyme (Section 2.2).
Both approaches rely on the incorporation of a metal-
containing catalyst in a binding pocket provided by the
protein. To ensure unambiguous localization of the coenzyme,
the host protein must contain a binding site or a unique
functionality which reacts (quasi) irreversibly with the
coenzyme or a portion thereof (the anchor) (Fig. 1).
2.1. Covalent anchoring
Kaiser was the first to demonstrate that novel active sites can
be introduced into enzymes by the chemical modification of
specific amino acid residues with the use of appropriately
designed coenzyme analogs.24 His group described that papain
can be converted into a highly effective oxido-reductase by
covalent modification of the sulfhydryl group of the active site
cysteine residue (Cys25) with flavins (Fig. 2). The resulting
flavopapains react with dihydronicotinamides and exhibit rate
enhancements (up to 670 fold) over native enzymes.
Inspired by this work, several groups have recently
developed methods to covalently modify proteins by incorpor-
ating transition-metal complexes to yield hybrid catalytic
systems with promising catalytic properties. Among these,
Rana and Meares have investigated the use of ferrous-EDTA
as metal chelate for the incorporation of transition metals into
proteins.25 Site-specific conjugation with either bovine serum
albumin or human carbonic anhydrase I (BSA and HCA I
respectively) was achieved by alkylation of the only
free sulfhydryl (Cys34 and Cys212 respectively) with
1-(p-bromoacetamidobenzyl)-EDTA. The chelating group
was loaded with an Fe(III) salt and the resulting artificial
metalloenzymes were shown to perform intramolecular (i.e.
single turnover) protein cleavage with a high regiospecificity,
yielding three- and two protein fragments respectively (for
BSA and HCA I conjugates).25
Building on earlier work on thiolsubtilisin and from the
unique chemistry of selenium, Hilvert developed a methodol-
ogy for the conversion of the active site serine of subtilisin
(Ser221) into selenocysteine.26,27 The semisynthetic enzyme
was shown (i) to function as an acyl transferase and (ii) to be
able to mimic the catalytic behavior of glutathione peroxidase.
Selenosubtilisin catalyzes the reduction of alkyl hydroper-
oxides by thiols. The reduction of tert-butyl hydroperoxide
(t-BuOOH) by 3-carboxy-4-nitrobenzenethiol catalyzed by
selenosubtilisin occurred at least 70 000-fold faster compared
to the same reaction catalyzed by diphenyl diselenide, a well-
studied antioxidant. The selenosubtilisin-catalyzed reaction
proceeds through a ‘‘ping-pong’’ mechanism involving at least
one covalent intermediate as depicted in Fig. 3.
Moving towards enantioselective artificial metalloenzymes,
Distefano and coworkers have reported the preparation of a
1,10-phenanthroline conjugate of an adipocyte lipid binding
protein (ALBP–Phen). Iodoacetamido-1,10-phenanthroline
reacts with the unique cysteine residue (Cys117) located in
the interior of ALBP to afford a phenanthroline linked via a
thioether. The semisynthetic apo-enzyme was loaded with
Cu(II) and the resulting ALBP–Phen–Cu(II) was found to
catalyze the enantioselective hydrolysis of several unactivated
amino acid ester substrates (0.7–7.6 TON, ee 31–86%, rates
32–280 above background, Fig. 4).28
In the area of catalytic antibodies, several groups have
covalently modified haptens to introduce a metal-containing
moiety. Janda and coworkers described the preparation of a
semisynthetic copper(II)-based catalytic antibody, by altering
the sidechain of the active-site lysine of catalytic antibody
38C2 to an imide-linked bisimidazole sidechain.29 The
authors were able to switch an aldolase catalytic antibody
into a metalloprotease-like one. The resulting 38C2-Cu
conjugate is an active catalyst for the hydrolysis of a
coordinating ester, following Michaelis–Menten kinetics
[kcat 5 2.3 min
21 and Km 5 2.2 mM] with a rate enhancement
[kcat/kuncat] 5 2.1 6 10
5.
In the past years, Reetz has beautifully demonstrated the
possibility of optimizing the selectivity of several, active but
unselective, enzymes by directed-evolution methods. This
approach relies on iterative cycles of random mutagenesis
coupled with an efficient enantioselectivity-screening proce-
dure. Having identified a mutant enzyme (obtained by random
mutagenesis) which displays an increased selectivity over the
previous generation, the gene encoding the protein is re-
subjected to a cycle of random mutagenesis, in the spirit of a
Darwinistic evolutionary process.18
By extension of this concept, Reetz proposed to extend this
methodology to evolve ‘‘hybrid catalysts’’ containing metal
coenzymes. Thus far, they were successful in introducing
various ligands and complexes thereof in the binding site of a
papain (Fig. 5). The nucleophilic cysteine of papain was
covalently modified by reaction with maleimide-derivatized
ligands (salen, dipyridine, diphosphine). Preliminary catalytic
experiments show that the hybrid manganese–salen and the
hybrid rhodium–dipyridine catalysts are active in epoxidation
and hydrogenation. However, low enantioselectivities
(,10% ee) were observed in all cases. Alternatively, phosphine
ligands bearing a para-nitrophosphonate funtionality can be
covalently linked to the serine residue in the active site of a
lipase. Unfortunately, this derivatization proved to be
reversible. Parallelization, miniaturization of expression,
Fig. 1 Anchoring of an active catalyst within a chiral host to produce
hybrid catalysts.
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protein purification, and chemical modification have yet to be
accomplished.17,18
2.2. Supramolecular anchoring
Wilson and Whitesides were the first to convert a protein into
an homogeneous enantioselective hydrogenation catalyst.30 As
early as 1978, they described an approach for the construction
of an asymmetric hydrogenation catalyst based on embedding
an achiral biotinylated rhodium–diphosphine moiety within
avidin. Since the first coordination sphere of the catalyst is
achiral, the protein cavity provides the chiral environment for
the enantioselective hydrogenation. Avidin is a well character-
ized protein composed of four identical subunits, each of
which binds biotin and many of its derivatives sufficiently
tightly that association is effectively irreversible.31 For the
reduction of acetamidoacrylate in avidin using N,N-bis(2-
diphenylphosphinoethyl)biotinamide in conjunction with
Rh(I)(norbornadiene), they reported an ee 5 39% in favour
of the (S)-acetamidoalanine (Fig. 6a).
The experiments reported by Whitesides establish two
principles:
(i) It is possible to carry out homogeneous hydrogenation
using a {Rh(diphosphine)}+ catalyst associated with a protein:
neither the aqueous solution nor interactions between the
metal and the protein deactivate the catalyst.
(ii) The chirality of the protein can induce significant levels
of enantioselectivity.
Fig. 3 Mechanism of reactions catalyzed by selenosubtilisin.
Fig. 4 (a) Preparation of ALBP–Phen–Cu(II) conjugates. (b)
Enantioselective hydrolysis of amino acid ester derivatives catalyzed
by ALBP–Phen–Cu(II).
Fig. 5 Covalent attachment of Mn–salen derivatives, Cu-, Pd- and
Rh dipyridine complexes and diphosphine moiety in a protein.
Fig. 2 (a) Examples of flavopapain derivatives synthesized by Kaiser. (b) Reaction catalyzed by flavopapains.
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Subsequently, Chan reported the use of an enantiopure
biotinylated pyrphos-Rh(I) complex in conjunction with avidin
for the enantioselective reduction of itaconic acid.32 By
introducing a chiral {Rh(I)(pyrphos)}+ moiety into the protein
cavity, it was found that the enantioselectivity of the system for
the asymmetric hydrogenation of itaconic acid was signifi-
cantly influenced by the presence of the host protein. Indeed,
when combined with avidin, both (R,R)- and (S,S)-pyrphos
yield the same enantiomer (R)-methylsuccinic acid with 11% ee
and 48% ee respectively. Furthermore, they showed that the
enantioselectivity critically depends on various parameters,
including H2 pressure, temperature and pH: by increasing the
temperature from 22 uC to 40 uC, the absolute configuration of
the product switches from 48% (R) to 20% (S) (Fig. 6b).
Using standard solid phase synthesis, Imperiali and Roy
introduced a pyridoxamine cofactor, in the middle of the
C-peptide derived from RNase S.33 This synthetic tetradeca-
peptide which forms an alpha-helix, contains a pyridoxamine
in position 8 and displays micromolar affinity for the RNase S.
When loaded with Cu(II), the resulting artificial metalloen-
zyme exhibited a seven fold faster transamination of pyruvate
to alanine for the first non-catalytic turnover of the enzyme.
Upon addition of phenylalanine to recycle the catalyst
however, the reaction became slower than with the free
pyridoxamine, but chiral inductions up to 31% ee were
obtained (Fig. 7).
More recently, Watanabe reported the insertion of achiral
Cr(III) complexes into the active site of apomyoglobin
(Fig. 8).34 In myoglobin, histidine-93 binds an iron-porphyrin
with a distal histidine-64 on the opposite face. Double-point
mutation (His64Asp, Ala71Gly) of apomyoglobin allowed the
incorporation of a {(Salophen)Cr(III)}+ complex. Upon
incorporation into the apo-myoglobin binding site, the
chromium is thought to complete its coordination by binding
to His93. These semisynthetic metalloenzymes were found to
catalyze the enantioselective sulfoxidation of thioanisole using
H2O2 as oxidant (up to 13% ee).
In the area of metal-containing catalytic antibodies, a few
promising results have been obtained using robust porphyrin-
containing haptens for immunization. The design of a metal-
containing hapten is a nontrivial task because, in addition to
mimicking the transition state, this hapten should have
considerable hydrolytic stability under the physiological
conditions during the immunization process.35
Following immunization, screening for binding of the
antibodies, isolation and purification, the antibody is loaded
with a porphyrin cofactor containing an active metal and
tested in catalysis. Using this strategy, the enantioselective
sulfoxidation of thioanisole was reported in two instances with
promising enantioselectivities.
For immunization, Keinan and coworkers used a water-
soluble tin(IV)–porphyrin hapten containing an axial
a-naphtoxy ligand to mimick the transition state of the
sulfoxidation of thio-anisole.36 The catalytic assembly com-
prising antibody SN37.4 and a ruthenium(II) porphyrin
cofactor exhibit typical Michaelis–Menten saturation kinetics.
In the presence of PhIO as oxidant, thioanisole is oxidized to
the corresponding sulfoxide with 43% ee in favour of the
(S)-methylphenylsulfoxide (Fig. 9a).
Suspecting that the presence of a fifth ligand completing the
coordination of the metal porphyrin is critical for activity (and
is not elicited upon immunization with a metal–porphyrin
hapten), Mahy and coworkers used microperoxidase 8 (MP8),
a heme octapeptide where the imidazole side chain of histidine
acts as a proximal ligand of the iron atom.37 After immuniza-
tion with MP8, they found that the 3A3-MP8 antibody–
coenzyme combination catalyzes the epoxidation of
thioanisole with 45% ee in favour of the (R)-enantiomer
(Fig. 9b). The MP8 cofactor was found to produce essentially
racemic sulfoxide in the absence of the antibody.
Fig. 6 (a) Enantioselective hydrogenation of acetamidoacrylic acid catalyzed by Whitesides’ system. (b) Enantioselective hydrogenation of
itaconic acid catalyzed by Chan’s system.
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Using rhodium loaded human serum albumin (HSA),
Marchetti and coworkers reported the hydroformylation of
styrene under biphasic conditions.38 Although the localization
of the rhodium catalyst is ill-defined (no anchoring), they
report very high turnover numbers (.500 000) and good
regioselectivites. For the hydroformylation of styrene, a
regioselectivity is 9 : 1 in favour of the branched isomer is
reported. Unfortunately, no mention of the enantioselectivity
is made (Fig. 10).
Recently, Watanabe reported a strategy for the construction
of a size-selective hydrogenation biocatalyst. They described
the encapsulation of a Pd cluster in the apo-ferritin cavity, an
iron-storage protein comprising 24 subunits that assemble to
form a hollow cagelike structure of 12 nm in diameter
(Fig. 11).39 This Pd(0)-loaded-ferritin system was able to
catalyze the hydrogenation of different acrylamide derivatives
in water.
Based on the reports summarized above, we speculated that
the most promising system to build upon is the biotin–avidin
system first investigated by Whitesides. As no chemical
coupling step is required upon addition of the catalyst
precursor to the protein, we reasonned that the integrity of
the organometallic species is warranted, thus ensuring a
well defined- and localized coenzyme within the host
protein. Furthermore, this system should be amenable to
both chemical- and genetic optimization procedures (i.e.
chemogenetic):
(i) The valeric acid side chain of biotin can readily be
derivatized by various amino acids, which in turn may be
coupled via an amide bond to the chelating ligand containing
an amine functionality. This chemical optimization allows to
probe the topography of the protein in search of a favourable
chiral environment.
(ii) Avidin has been expressed in various organisms; it is a
very robust protein which can easily be purified via affinity
chromatography (on an iminobiotin resin).
As a model reaction, prototypical of homogeneous catalysis,
we focused on the hydrogenation of N-protected dehydro-
amino acids (e.g. acetamidoacrylate). Two different biotiny-
lated ligand scaffolds Biot–1 and Biot–2 were selected and
tested in the presence of Rh(I) salts. In agreement with both
Withesides’ and Chan’s observation, we found that the
biotinylated ligands devoid of spacer give modest levels of
enantioselection (Biot–1 : 39% ee (S), Biot–2 : 0% ee).40
Next, we introduced a spacer between the anchor (biotin)
and the metal diphosphine moiety. The introduction of a
glycine spacer 31 has a positive influence on the enantioselec-
tivity to afford 57% (S) and 80% (S) using Biot–31–1 and biot–
31–2 as ligands in avidin (Fig. 12).
Streptavidin is also a biotin-binding protein isolated from
Streptomyces avidini. Although both avidin and streptavidin
display similar affinities for biotin, they possess only y35%
primary sequence homology. Inspection of both protein
monomers reveals that the major structural difference is that
Fig. 7 Structures of intermediates in the Cu(II)-assisted transamination of pyruvate to alanine by Pam-containing peptides.
Fig. 8 (a) Salophen complex inserted into apo-Mb. (b) Sulfoxidation
of thioanisole catalyzed by apo-Mb-Cr(Salophen).
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streptavidin is endowed with a deeper binding pocket
(Fig. 13).31
Using streptavidin as a host protein, we found that, in the
presence of Biot–1, the reduction of acetamidoacrylate
proceeds with 94% ee in favour of the (R)-enantiomer.
Having identified a host protein–ligand combination afford-
ing high levels of enantioselection, site-directed mutagenesis
was performed on position Ser112 of wild-type streptavidin.
This position was selected as molecular modelling suggests
that it lies close to the rhodium center upon incorporation
of the coenzyme [Rh(COD)(Biot–1)]+ in streptavidin
([Rh(COD)(Biot–1)]+ , SAV). The streptavidin mutant
Ser112Gly was thus produced in E. coli, purified on an
iminobiotin column and screened with various ligands-spacer
combinations for the reduction of acetamidoacrylate. With
Biot–1, a slight increase in enantioselectivity was observed
(96% ee (R), compared to 94% ee (R) for WT SAV).
Interestingly, in the combination with Biot–31–2, the
Ser112Gly mutant produces preferentially the
(S)-acetamidoalanine: 31% ee (S) vs. 31% ee (R) for WT SAV.
In order to test the substrate specificity, acetamidocinna-
mate was tested as substrate for the hydrogenation in
streptavidin in the presence of Biot–1. This bulkier substrate
Fig. 9 (a) Hapten used by Keinan. (b) Coenzyme used by Keinan. (c) Hapten and coenzyme used by Mahy. (d) Reaction catalyzed by Keinan’s
and Mahy’s systems.
Fig. 10 Hydroformylation of styrene catalyzed by HSA-Rh(I)
system.
Fig. 11 (a) Structure of ferritin. (b) Examples of olefin hydrogenation
catalyzed by the Pd-loaded ferritin.
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was hydrogenated withing 8 h at rt to produce
(R)-acetamidophenylalanine quantitatively with an 86% ee.
Having demonstrated the beneficial effect of the second
coordination sphere provided by the protein on the selectivity,
we determined the influence of the host protein on the activity
of the hybrid catalyst.41 For this purpose, the tetrameric
streptavidin was loaded with increasing amounts of
[Rh(COD)(Biot–1)]+ (1–10 equivalents). Beyond four equiva-
lents of coenzyme, the optical purity of the produced
acetamidoalanine steadily decreases, as the catalyst outside
of the protein affords essentially racemic material. The
enantioselectivity obtained was however higher that the
predicted—considering that both catalytic cycles (inside- and
outside the protein) proceed according to the same mechan-
ism—a rate acceleration of three was estimated for the protein-
embedded catalyst ([Rh(COD)(Biot–1)]+ , SAV). It thus
appears that the protein environment has a beneficial effect
both on the selectivity and on the activity of these artificial
metalloenzymes.42
3. Outlook
In the Introduction, we outlined the pros and cons of
homogeneous- and enzymatic catalysis (Table 1). Having
reviewed the state-of-the art in the area of enantioselective
artificial metalloenzymes, we now critically discuss whether
such systems indeed offer the best of both worlds.
By varying the position of the coenzyme within the chiral
cavity by introduction of a spacer between the anchor and the
ligand, it is possible to obtain both enantiomers of the product.
In addition, genetic optimization can also lead to the inversion
Fig. 12 Biotinylated ligands synthesized.
Fig. 13 Comparison of the structure of avidin (a) and streptavidin (b) (only one monomer incorporating biotin depicted; hydrophobic binding
pocket residues highlighted).
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of the enantioselectivity. In the hydrogenation reaction
described above, using the streptavidin mutant Ser112Gly,
acetamidoalanine is produced in 96% ee (R) using Biot–1 in
and in 57% ee (S) using Biot–4ortho–2 (Fig. 12).
The introduction of an organometallic catalyst precursor in
a protein broadens the scope of applications of enzymes.
Although enantioselective hydrogenases exist,43 these are more
typical reactions of the organometallic kingdom. To the best of
our knowledge, no hydroformylation enzyme exists. Ideally,
one could envisage the incorporation of any organometallic
catyst (which is compatible with water) within a protein to
produce a hybrid catalyst.
The introduction of a metal in a protein imposes stringent
limitations on the stability of the hybrid catalyst. For example,
as the protein cavity is lypophilic, we have found that oxygen
traces are difficult to remove and may cause catalyst
deactivation if this latter is air-sensitive. We are currently
investigating different metal-catalyzed reactions where oxygen
is not a problem, but the (homogeneous) catalyst dimerization
is a major deactivation pathway. We expect the corresponding
hybrid catalyst with isolated metal sites to display high
turnover numbers as the deactivation pathway is inhibited.
The solvent compatibility of the artificial metalloenzyme is
by-and-large dictated by the protein stability in organic
solvents. Thus far, the research on such systems has been
performed in aqueous or biphasic solutions, perhaps contain-
ing a few percent organic solvent to solubilize the organome-
tallic species and/or the substrate.
Concerning the second coordination sphere, the production
of enantiomerically enriched products, suggests that the metal
coenzyme is indeed embedded in the chiral environment
provided by the protein. The extent of incorporation depends
on the catalyst–protein couples, and certainly deserves
thorough investigation by NMR or by X-ray analysis.
As the host protein’s binding pocket was by no means
optimized by Nature to accomodate an enantiodiscriminating
catalytic event, further developments should focus on tailoring
the ‘‘active’’ site to favour a desired catalytic cycle. This may
best be achieved by site-directed introduction of a suitably
positionned amino acid residue with a side-chain capable of
interacting either with the metal or with the prochiral
substrate. These improvements may allow to render the hybrid
catalysts more ‘‘enzyme’’-like in terms of substrate specificity
and functional group tolerance.
As discussed above, the optimization of artificial metalloen-
zymes can be performed with both chemical and genetic
means. Combining these powerful tools opens fascinating
perspectives in the discovery and the optimization of new
artificial metalloenzymes for enantioselective catalysis.
Following submission of this review, Lu and coworkers
reported a Mn(Schiff-base) covalently modified apo-
myoglobin for the enantioselective oxidation of thioanisole
(Fig. 14).44 Introduction of two cysteine residues (Tyr103Cys
and Leu72Cys) allows to tightly anchor via two thioether
tethers the metallo-coenzyme (which additionally interacts
with His93). This dual anchoring strategy proved superior to
both the mono-anchored and to the ‘‘supramolecular’’
anchoring reported by Watanabe.34 This exciting contribution
demonstrates that both covalent- and supramolecular
anchoring strategies are equally suited to develop artificial
metalloenzymes for enantioselective catalysis.
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